We found that MAPK inhibition failed to reduce the MCM2 rate in control adenocarcinomas, whereas the MCM2 rate declined in tumors with Cyclin D2 knockdown upon RAF/MEK inhibitor treatment (Figure 5J). This evidence concerns the gene MCM2 and adenocarcinoma.